210 related articles for article (PubMed ID: 17438408)
1. Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression.
Chen YW; Smith ML; Sheets M; Ballaron S; Trevillyan JM; Burke SE; Rosenberg T; Henry C; Wagner R; Bauch J; Marsh K; Fey TA; Hsieh G; Gauvin D; Mollison KW; Carter GW; Djuric SW
J Cardiovasc Pharmacol; 2007 Apr; 49(4):228-35. PubMed ID: 17438408
[TBL] [Abstract][Full Text] [Related]
2. Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks.
Garcia-Touchard A; Burke SE; Toner JL; Cromack K; Schwartz RS
Eur Heart J; 2006 Apr; 27(8):988-93. PubMed ID: 16449248
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of rapamycin, cyclosporine A, and FK506 on human coronary artery smooth muscle cell proliferation and signalling.
Hafizi S; Mordi VN; Andersson KM; Chester AH; Yacoub MH
Vascul Pharmacol; 2004; 41(4-5):167-76. PubMed ID: 15607500
[TBL] [Abstract][Full Text] [Related]
4. Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells.
Matter CM; Rozenberg I; Jaschko A; Greutert H; Kurz DJ; Wnendt S; Kuttler B; Joch H; Grünenfelder J; Zünd G; Tanner FC; Lüscher TF
J Cardiovasc Pharmacol; 2006 Dec; 48(6):286-92. PubMed ID: 17204907
[TBL] [Abstract][Full Text] [Related]
5. Effects of drug combinations on smooth muscle cell proliferation: an isobolographic analysis.
Parry TJ; Thyagarajan R; Argentieri D; Falotico R; Siekierka J; Tallarida RJ
Eur J Pharmacol; 2006 Feb; 532(1-2):38-43. PubMed ID: 16448648
[TBL] [Abstract][Full Text] [Related]
6. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery.
Wessely R; Blaich B; Belaiba RS; Merl S; Görlach A; Kastrati A; Schömig A
Thromb Haemost; 2007 Jun; 97(6):1003-12. PubMed ID: 17549304
[TBL] [Abstract][Full Text] [Related]
7. Sirolimus PK trial: a pharmacokinetic study of the sirolimus-eluting Bx velocity stent in patients with de novo coronary lesions.
Vetrovec GW; Rizik D; Williard C; Snead D; Piotrovski V; Kopia G
Catheter Cardiovasc Interv; 2006 Jan; 67(1):32-7. PubMed ID: 16342216
[TBL] [Abstract][Full Text] [Related]
8. FK778 in experimental xenotransplantation: a detailed analysis of drug efficacy.
Schrepfer S; Deuse T; Koch-Nolte F; Krieger T; Haddad M; Schäfer H; Pelletier MP; Robbins RC; Reichenspurner H
J Heart Lung Transplant; 2007 Jan; 26(1):70-7. PubMed ID: 17234520
[TBL] [Abstract][Full Text] [Related]
9. Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries.
Parry TJ; Brosius R; Thyagarajan R; Carter D; Argentieri D; Falotico R; Siekierka J
Eur J Pharmacol; 2005 Nov; 524(1-3):19-29. PubMed ID: 16271360
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus and FK778: a comparison of two anti-proliferative immunosuppressants for prevention of experimental obliterative airway disease.
Deuse T; Schrepfer S; Koch-Nolte F; Haddad M; Schäfer H; Detter C; Reichenspurner H
Transpl Int; 2006 Apr; 19(4):310-8. PubMed ID: 16573547
[TBL] [Abstract][Full Text] [Related]
11. Zotarolimus (ABT-578) eluting stents.
Burke SE; Kuntz RE; Schwartz LB
Adv Drug Deliv Rev; 2006 Jun; 58(3):437-46. PubMed ID: 16581153
[TBL] [Abstract][Full Text] [Related]
12. Progesterone induces human leukocyte antigen-g expression in vascular endothelial and smooth muscle cells.
Sheshgiri R; Rao V; Tumiati LC; Xiao R; Prodger JL; Badiwala M; Librach C; Delgado DH
Circulation; 2008 Sep; 118(14 Suppl):S58-64. PubMed ID: 18824770
[TBL] [Abstract][Full Text] [Related]
13. Comparative assessment of transient exposure of paclitaxel or zotarolimus on in vitro vascular cell death, proliferation, migration, and proinflammatory biomarker expression.
Steinfeld DS; Liu AP; Hsu SH; Chan YF; Stankus JJ; Pacetti SD; Tai JT
J Cardiovasc Pharmacol; 2012 Aug; 60(2):179-86. PubMed ID: 22561362
[TBL] [Abstract][Full Text] [Related]
14. Orally administered rapamycin does not modify rat aortic vascular tone.
Neto Mde M; Di Marco GS; Casarini DE; Lima VC; Campos AH
J Cardiovasc Pharmacol; 2007 Feb; 49(2):96-9. PubMed ID: 17312450
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effect of vincristine with tacrolimus or sirolimus in prevention of acute heart allograft rejection in the rat.
Jiang W; Jiang J; Xu D; Wang X; Qi S; Ouyang J; Ma A; Vu MD; Bilolo KK; Chen H
Microsurgery; 2003; 23(2):117-22. PubMed ID: 12740883
[TBL] [Abstract][Full Text] [Related]
17. Overview of a 10-year experience on methods and compositions for inducing site-specific immunosuppression with topical immunosuppressants.
Hewitt CW; Black KS
Transplant Proc; 1996 Apr; 28(2):922-3. PubMed ID: 8623464
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus increases tissue factor expression but not activity in cultured human vascular smooth muscle cells.
Zhu S; Viswambharan H; Gajanayake T; Ming XF; Yang Z
BMC Cardiovasc Disord; 2005 Jul; 5():22. PubMed ID: 16018822
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of restenosis development after mechanical injury: a new field of application for malononitrilamides?
Schrepfer S; Deuse T; Sultan KR; Haddad M; Böger R; Münzel T; Schäfer H; Pelletier MP; Robbins RC; Reichenspurner H
Cardiology; 2007; 108(2):128-37. PubMed ID: 17028423
[TBL] [Abstract][Full Text] [Related]
20. Neointimal expression of rapamycin receptor FK506-binding protein FKBP12: postinjury animal and human in-stent restenosis tissue characteristics.
Bauriedel G; Jabs A; Kraemer S; Nickenig G; Skowasch D
J Vasc Res; 2008; 45(2):173-8. PubMed ID: 17962721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
